Always tough to identify an inflexion point in advance, especially with a biotech but ultimately it comes down to sales and regulatory approvals.
Last quarter sales were disappointing but all it takes is a quarter or two of significant growth and people are pretty quick to do the math on the compounding. Hopefully this quarter growth is sufficient to make the numbers look compelling.
Ann: Part 1 Remplir US Market Authorisation Successfully Complete, page-33
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $75.35M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 36.5¢ | 36.0¢ | $21.77K | 60.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 151293 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 39200 | 2 |
View Market Depth
| Last trade - 15.22pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
36.0¢ |
Change
-0.010 ( 1.37 %) |
||||
| Open | High | Low | Volume | ||
| 36.5¢ | 36.5¢ | 36.0¢ | 13917 | ||
| Last updated 15.22pm 17/06/2024 ? | |||||
| OCC (ASX) Chart |
